Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006–10 study - Ruiz-Borrego, M; Guerrero-Zotano, A; Bermejo, B (Breast Cancer Res Treat, 2019)
et al.